Title of article :
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Author/Authors :
Beatriz Grinsztejn، نويسنده , , Bach-Yen Nguyen، نويسنده , , Christine Katlama، نويسنده , , José M Gatell، نويسنده , , Adriano Lazzarin، نويسنده , , Daniel Vittecoq، نويسنده , , Charles J Gonzalez، نويسنده , , Joshua Chen، نويسنده , , Charlotte M Harvey، نويسنده , , Robin D Isaacs ، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Pages :
9
From page :
1261
To page :
1269
Abstract :
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs. The aim of this study was to assess the safety and efficacy
Journal title :
The Lancet
Serial Year :
2008
Journal title :
The Lancet
Record number :
591199
Link To Document :
https://search.isc.ac/dl/search/defaultta.aspx?DTC=10&DC=591199
بازگشت